Literature DB >> 9855358

Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans.

R Eleopra1, V Tugnoli, O Rossetto, D De Grandis, C Montecucco.   

Abstract

Botulinum toxin serotypes A and E (BoNT/A and /E) cleave the carboxy-terminus of synaptosomal associated protein-25 (SNAP-25) removing nine and 26 residues, respectively. To investigate the effect of these lesions of the same target molecule, 11 volunteers were injected with 3 IU of BoNT/A in the extensor digitorum brevis (EDB) muscle of one foot and with 3 IU of BoNT/E in the contralateral one. In addition, seven volunteers were similarly injected with mixtures of BoNT/A + BoNT/E. Compound muscular action potential (CMAP) was measured at different time intervals and the percentage variation of CMAP (%CMAP) was calculated. Unexpectedly, a much faster recovery of %CMAP after BoNT/E injections was observed. Double poisoned EBD muscles recovered similarly to BoNT/E. So, a larger deletion of the SNAP-25 molecule caused by BoNT/E leads to a faster functional recovery.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855358     DOI: 10.1016/s0304-3940(98)00775-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  47 in total

1.  A molecular basis underlying differences in the toxicity of botulinum serotypes A and E.

Authors:  Mark Bajohrs; Colin Rickman; Thomas Binz; Bazbek Davletov
Journal:  EMBO Rep       Date:  2004-11       Impact factor: 8.807

Review 2.  Neurophysiological effects of botulinum toxin type A.

Authors:  G Abbruzzese; A Berardelli
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 3.  Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting.

Authors:  B R Singh
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 4.  The blockade of the neurotransmitter release apparatus by botulinum neurotoxins.

Authors:  Sergio Pantano; Cesare Montecucco
Journal:  Cell Mol Life Sci       Date:  2013-06-11       Impact factor: 9.261

Review 5.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

6.  Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA").

Authors:  Sabine Pellett; William H Tepp; Guangyun Lin; Eric A Johnson
Journal:  Toxicon       Date:  2017-12-19       Impact factor: 3.033

7.  Novel Native and Engineered Botulinum Neurotoxins.

Authors:  Lance Steward; Mitchell F Brin; Amy Brideau-Andersen
Journal:  Handb Exp Pharmacol       Date:  2021

Review 8.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

9.  Novel Benzimidazole Inhibitors of Botulinum Neurotoxin/A Display Enzyme and Cell-Based Potency.

Authors:  Steven C Cardinale; Michelle M Butler; Gordon Ruthel; Jonathan E Nuss; Laura M Wanner; Bing Li; Ramdas Pai; Norton P Peet; Sina Bavari; Terry L Bowlin
Journal:  Botulinum J       Date:  2011

10.  Long-lasting attenuation of amygdala-kindled seizures after convection-enhanced delivery of botulinum neurotoxins a and B into the amygdala in rats.

Authors:  Maciej Gasior; Rebecca Tang; Michael A Rogawski
Journal:  J Pharmacol Exp Ther       Date:  2013-06-14       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.